top of page

Vanda Pharmaceuticals scores second FDA approval in 2 months

Washington Business Journal

Feb 23

1 min read

Updated: Mar 24

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) has landed another regulatory approval, this time for a schizophrenia and bipolar treatment - two months after securing a nod to take a motion sickness medication to market...

Recent Posts

See All

Maryland Awards $8.5 Million to Expand University Research Chairs Through $17.7 Million Innovation Initiative

Taiwan-Based Bora Biologics Expands With $122.5M Rockville Acquisition

Top 10 U.S. Biopharma Clusters 2026

Comments

bottom of page